Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Database
Country/Region as subject
Language
Affiliation country
Publication year range
1.
Eur Stroke J ; 8(4): 942-946, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37489615

ABSTRACT

INTRODUCTION: The New Zealand (NZ) Central Region Stroke Network, serving 1.17 million catchment population, changed to tenecteplase for stroke thrombolysis in 2020 but was forced to revert to Alteplase in 2021 due to a sudden cessation of drug supply. We used this unique opportunity to assess for potential before and after temporal trend confounding. PATIENTS AND METHODS: In NZ all reperfused patients are entered prospectively into a national database for safety monitoring. We assessed Central Region patient outcomes and treatment metrics over three time periods: alteplase use (January 2018-January 2020); during switch to tenecteplase (February 2020-February 2021) and after reverting to alteplase (February 2021-December 2022) adjusting regression analyses for hospital, age, onset-to-needle, NIHSS, pre-morbid mRS and thrombectomy. RESULTS: Between January 2018 and December 2022, we treated 1121 patients with Alteplase and 286 with tenecteplase. Overall, patients treated with tenecteplase had greater odds of favorable outcome ordinal mRS [aOR = 1.43 (95% CI = 1.11-1.85)]; shorter door-to-needle (DTN) time [median 52 (IQR 47-83) vs 61 (45-84) minutes, p < 0.0001] and needle to groin (NTG) times [118 (74.5-218.5) vs 185 (118-255); p = 0.02)]. Symptomatic intracerebral hemorrhage (sICH) rate was lower in tenecteplase group [aOR 0.29 (0.09-0.95)]. Findings similarly favored tenecteplase when comparing tenecteplase to only the second alteplase phase. There was no inter-group difference when comparing the two alteplase phases. CONCLUSIONS: Our results suggest that previously reported benefits from tenecteplase in a real-world setting were not likely attributable to a temporal confounding.


Subject(s)
Brain Ischemia , Stroke , Humans , Tenecteplase/therapeutic use , Tissue Plasminogen Activator/therapeutic use , Fibrinolytic Agents/adverse effects , Brain Ischemia/chemically induced , Stroke/drug therapy
2.
Eur Stroke J ; 8(1): 191-198, 2023 03.
Article in English | MEDLINE | ID: mdl-37021178

ABSTRACT

Introduction: The very elderly (⩾80 years) are under-represented in randomised endovascular thrombectomy (EVT) clinical trials for acute ischaemic stroke. Rates of independent outcome in this group are generally lower than the less-old patients but the comparisons may be biased by an imbalance of non-age related baseline characteristics, treatment related metrics and medical risk factors. Patients and methods: We compared outcomes between very elderly (⩾80) and the less-old (<80 years) using retrospective data from consecutive patients receiving EVT from four comprehensive stroke centres in New Zealand and Australia. We used propensity score matching or multivariable logistic regression to account for confounders. Results: We included 600 patients (300 in each age cohort) after propensity score matching from an initial group of 1270 patients. The median baseline National Institutes of Health Stroke Scale was 16 (11-21), with 455 (75.8%) having symptom free pre-stroke independent function, and 268 (44.7%) receiving intravenous thrombolysis. Good functional outcome (90-day modified Rankin Scale 0-2) was achieved in 282 (46.8%), with very elderly patients having less proportion of good outcome compared to the less-old (118 (39.3%) vs 163 (54.3%), p < 0.01). There was no difference between the very elderly and the less-old in the proportion of patients who returned to baseline function at 90 days (56 (18.7%) vs 62 (20.7%), p = 0.54). All-cause 90-day mortality was higher in the very elderly (75 (25%) vs 49 (16.3%), p < 0.01), without a difference in symptomatic haemorrhage (very elderly 11 (3.7%) vs 6 (2.0%), p = 0.33). In the multivariable logistic regression models, the very elderly were significantly associated with reduced odds of good 90-day outcome (OR 0.49, 95% CI 0.34-0.69, p < 0.01) but not with return to baseline function (OR 0.85, 90% CI 0.54-1.29, p = 0.45) after adjusting for confounders. Conclusion: Endovascular thrombectomy can be successfully and safely performed in the very elderly. Despite an increase in all-cause 90-day mortality, selected very elderly patients are as likely as younger patients with similar baseline characteristics to return to baseline function following EVT.


Subject(s)
Brain Ischemia , Endovascular Procedures , Ischemic Stroke , Stroke , Humans , Aged , Stroke/surgery , Brain Ischemia/surgery , Retrospective Studies , Propensity Score , Treatment Outcome , Endovascular Procedures/adverse effects , Thrombectomy/adverse effects , Ischemic Stroke/surgery
3.
Neurology ; 99(19): e2125-e2136, 2022 11 08.
Article in English | MEDLINE | ID: mdl-36240100

ABSTRACT

BACKGROUND AND OBJECTIVE: Stroke reperfusion therapy is time critical. Improving prehospital diagnostic accuracy including the likelihood of large vessel occlusion can aid with efficient and appropriate diversion decisions to optimize onset-to-treatment time. In this study, we investigated whether prehospital telestroke improves diagnostic accuracy when compared with paramedic assessments and assessed feasibility. METHODS: We conducted a pragmatic, community-based, cluster randomized controlled trial comparing the diagnostic accuracy of telestroke assessments inside the ambulance with a modified Los Angeles Motor Scale (PASTA score). The primary outcome was the accuracy of predicting reperfusion candidates; secondary outcomes were accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of either approach to identify IV thrombolysis (IVT) and endovascular thrombectomy (EVT) candidates and true stroke patients by study group. The accuracy of telestroke and PASTA assessments was compared against in-person assessment in the emergency department and with the final diagnosis/intervention for the patient. We also monitored for technical challenges. RESULTS: We recruited 76 patients (35 telestroke and 41 PASTA) between August 2019 and September 2020. The mean age was 72.2 (±14.6) years. Telestroke was 100% (95% CI 90%-100%) and PASTA 70.7% (54.5%-83.9%) accurate in predicting reperfusion candidates compared with preimaging emergency department neurologist assessment (p < 0.001). When compared with actual reperfusion therapy administered, the predictive accuracy was 80% (63.1%-91.6%) and 60.1% (44.5%-75.8%) for telestroke and PASTA, respectively (p < 0.001). In predicting the administration of IVT, telestroke was 80% (63.1-91.6) and PASTA was 56.1% (39.8-71.5) accurate (p < 0.001). In predicting intervention with EVT, telestroke was 88.6% (73.3-96.8) and PASTA 56.1% (39.8-71.5) accurate (p = 0.005). The service model proved technically feasible and was acceptable to neurologists. DISCUSSION: Prehospital telestroke assessment is feasible, accurate, and superior to the PASTA score in predicting acute reperfusion therapies, presenting an effective option to guide prehospital diversion decisions. TRIAL REGISTRATION: The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12619001678189).anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378655&isReview=true. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that intra-ambulance telestroke evaluation has a greater diagnostic accuracy compared with the PASTA score performed by paramedics in distinguishing hyperacute stroke patients who are candidates for reperfusion therapy.


Subject(s)
Stroke , Humans , Aged , Australia , Stroke/diagnosis , Stroke/therapy , Ambulances , Reperfusion , Allied Health Personnel
SELECTION OF CITATIONS
SEARCH DETAIL